The company reported strong first-quarter earnings and provided positive commentary for the long-term opportunity in physical ...
SLS stock soared more than 24% at close on Monday as investors looked ahead to the company’s Phase 3 REGAL trial results for its acute myeloid leukemia (AML) immunotherapy. ・BB stock rose more than 9% ...